Gui-Ling Chen, Yang Liu, Xue-Feng Gao, Kai-Qi Wu, Yun-Kai Yang, Yong Chen, Cong-Gao Peng, Ting-Han Jin, Yu-Bao Huang, Yao-Wen Zhang, Jing Su, Qi Jiang, Tong Guo, Jie Zhao, Xiang-Nan Peng, Jing-Yu Peng, Si-Xiu Li, Yong-Li Sun, Hong-Mei Zhang, Yan-Li Fu, Dan Luo, Yaru Ma, Zhen-Wei Shen, Yun-Tao Zhang, Zhang-Fei Shou
AIM: Novel long-acting drugs for type 2 diabetes mellitus may optimize patient compliance and glycaemic control. Exendin-4-IgG4-Fc (E4F4) is a long-acting glucagon-like peptide-1 receptor agonist. This first-in-human study investigated the safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of a single subcutaneous injection of E4F4 in healthy subjects. METHODS: This single-centre, randomized, double-blind, placebo-controlled phase 1 clinical trial included 96 subjects in 10 sequential cohorts that were provided successively higher doses of E4F4 (0...
January 29, 2024: Diabetes, Obesity & Metabolism